Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Company Strategy - The company has approved the purchase of Bitcoin as a treasury reserve asset to diversify its holdings and benefit from the potential long-term value of digital assets [1] - The company reaffirmed its ongoing stock buyback program as part of its commitment to enhancing shareholder value [2] - The decision to invest in Bitcoin is seen as an additional approach to prudent financial management, enabling greater shareholder value [3] - The company believes Bitcoin's growing recognition as a mainstream asset class, its inflation-resistant qualities, and potential as a reliable store of value align with its goal of optimizing long-term financial stability and growth [4] Clinical Trials and Pipeline - The company's breast cancer vaccine (NCT04674306) and ovarian cancer therapy (NCT05316129) have produced results that exceeded expectations [3] - The company's therapeutic portfolio includes an ovarian cancer immunotherapy program using CER-T technology, developed in collaboration with Moffitt Cancer Center [5] - The company's vaccine portfolio includes vaccines developed in collaboration with Cleveland Clinic to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting lung, colon, and prostate cancers [5] Business Model and Partnerships - The company's unique business model involves partnering with world-renowned research institutions for all stages of development, allowing it to continually examine emerging technologies in complementary fields for further development and commercialization [5]